Pfizer Inc. (NYSE:PFE) Stock Position Lowered by Brown Shipley& Co Ltd

Brown Shipley& Co Ltd trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 72.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,240 shares of the biopharmaceutical company’s stock after selling 14,076 shares during the period. Brown Shipley& Co Ltd’s holdings in Pfizer were worth $147,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Olistico Wealth LLC purchased a new position in Pfizer during the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC acquired a new stake in Pfizer in the 2nd quarter valued at approximately $29,000. Quarry LP acquired a new stake in shares of Pfizer in the second quarter worth $31,000. Creekmur Asset Management LLC acquired a new position in Pfizer during the 4th quarter valued at $32,000. Finally, Trivant Custom Portfolio Group LLC raised its position in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 0.4 %

NYSE PFE opened at $29.09 on Monday. The stock has a market capitalization of $164.84 billion, a P/E ratio of -484.83, a price-to-earnings-growth ratio of 1.27 and a beta of 0.68. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $34.11. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The stock has a fifty day moving average of $29.31 and a 200-day moving average of $28.30.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the previous year, the business posted $0.67 EPS. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Wells Fargo & Company upped their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday, September 16th. Finally, UBS Group boosted their target price on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.